参考文献/References:
[1] Becker RC, Gurbel PA. Platelet P2Y12 receptor antagonist pharmacokinetics and pharmacodynamics: a foundation for distinguishing mechanisms of bleeding and anticipated risk for platelet-directed therapies[J]. Thromb Haemost,2010,103(3):535-544.
[2] Husted S.Unmet needs in oral antiplatelet therapy with ADP receptor blocking agents[J]. Fundam Clin Pharmacol,2009,23(1):1-9.
[3] Windecker S, Kolh P, Alfonso F, et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology(ESC)and the European Association for Cardio-Thoracic Surgery(EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions(EAPCI)[J]. Eur Heart J,2014,35(37):2541-2619.
[4] Cheng JW. Ticagrelor: oral reversible P2Y(12)receptor antagonist for the management of acute coronary syndromes[J]. Clin Ther,2012,34(6):1209-1220.
[5] Gurbel PA, Bliden KP, Butler K, et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study[J]. Circulation,2009,120(25):2577-2585.
[6] Wallentin L, Becke RC, Buda A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes[J]. N Engl J Med,2009,361(11):1045-1057.
[7] Held C, Asenblad N, Bassand JP, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery:results from the PLATO(Platelet Inhibition and Patient Outcomes)trial[J]. J Am Coll Cardiol,2011,57(6):672-684.
[8] Steg PG, James S, Harrington RA, et al. Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes(PLATO)trial subgroup analysis[J]. Circulation,2010,122(21):2131-2141.
[9] Lindholm D, Varenhorst C, Cannon CP, et al. Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial[J]. Eur Heart J, 2014,35(31):2083-2093.
[10] de Luca G, Suryapranata H, Ottervanger JP, et al. Time delay to treatment and mortality in primary angioplasty for acute myocardial infarction:every minute of delay counts[J]. Circulation,2004,109(10):1223-1225.
[11] Montalescot G, van 't Hof AW, Lapostolle F, et al. Prehospital ticagrelor in ST-segment elevation myocardial infarction[J].N Engl J Med,2014,371(11):1016-1027.
[12] Norhammar A, Malmberg K, Diderholm E, et al. Diabetes mellitus:the major risk factor in unstable coronary artery disease even after consideration of the extent of coronary artery disease and benefits of revascularization[J]. J Am Coll Cardiol,2004,43(4):585-591.
[13] James S, Angiolillo DJ, Cornel JH, et al. Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes:a substudy from the PLATelet inhibition and patient Outcomes(PLATO)trial[J]. Eur Heart J,2010,31(24):3006-3016.
[14] Anavekar NS, McMurray JJ, Velazquez EJ, et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction[J]. N Engl J Med,2004,351(13):1285-1295.
[15] Butler K, Teng R. Pharmacokinetics, pharmacodynamics, and safety of ticagrelor in volunteers with severe renal impairment[J].J Clin Pharmacol,2012,52(9):1388-1398.
[16] James S, Budaj A, Aylward P, et al. Ticagrelor Versus Clopidogrel in Acute Coronary Syndromes in Relation to Renal Function: Results From the Platelet Inhibition and Patient Outcomes(PLATO)Trial[J]. Circulation, 2010,122(11):1056-1067.
[17] Washam JB, Herzog CA, Beitelshees AL, et al. Pharmacotherapy in chronic kidney disease patients presenting with acute coronary syndrome:a scientific statement from the American Heart Association[J]. Circulation, 2015,131(12):1123-1149.
[18] Subherwal S, Bach RG, Chen AY,et al.Baseline risk of major bleeding in non-ST-segment-elevation myocardial infarction: the CRUSADE(Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA Guidelines)Bleeding Score[J]. Circulation, 2009,119(14):1873-1882.
[19] Antman EM, Tanasijevic MJ, Thompson B, et al. Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes[J].N Engl J Med,1996,335(18):1342-1349.
[20] Bonaca MP, Bhatt DL, Cohen M, et al. Long-term use of ticagrelor in patients with prior myocardial infarction[J]. N Engl J Med,2015,372(19):1791-1800.
[21] Bonaca MP, Bhatt DL, Steg PG, et al. Ischaemic risk and efficacy of ticagrelor in relation to time from P2Y12 inhibitor withdrawal in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54[J].Eur Heart J,2015,pii: ehv531[Epub ahead of print].
[22] Amsterdam EA, Wenger NK, Brindis RG, et al.2014 AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes:a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines[J]. J Am Coll Cardiol, 2014,64(24):e139-e228.
[23] Storey RF, Angiolillo DJ, Patil SB, et al. Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO(PLATelet inhibition and patient Outcomes)PLATELET substudy[J]. J Am Coll Cardiol,2010,56(18):1456-1462.
[24] Verdoia M, Nardin M, Sartori C,et al. Impact of atorvastatin or rosuvastatin co-administration on platelet reactivity in patients treated with dual antiplatelet therapy[J].Atherosclerosis,2015,243(2):389-394.
[25] Lau WC. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction[J]. Circulation,2003,107(1):32-37.
[26] Montalescot G, Bolognese L, Dudek D, et al. Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes[J].N Engl J Med,2013,369(11):999-1010.
[27] Goto S, Huang CH, Park SJ, et al. Ticagrelor vs.clopidogrel in Japanese, Korean and Taiwanese patients with acute coronary syndrome—randomized, double-Blind, phase ⅢPHILO Study[J].Circ J, 2015,79(11):2452-2460.
[28] Qaderdan K, Ishak M, Heestermans AA, et al. Ticagrelor or prasugrel versus clopidogrel in elderly patients with an acute coronary syndrome:optimization of antiplatelet treatment in patients 70 years and older—rationale and design of the POPular AGE study[J]. Am Heart J, 2015,170(5):981-985.
相似文献/References:
[1]朱佩,袁晋青.P2Y12受体拮抗剂与质子泵抑制剂相互作用的研究进展[J].心血管病学进展,2015,(5):570.[doi:10.3969/j.issn.1004-3934.2015.05.012]
ZHU Pei,YUAN Jinqing.Review of Interactions Between P2Y12 Receptor Antagonists and
Proton Pump Inhibitors[J].Advances in Cardiovascular Diseases,2015,(3):570.[doi:10.3969/j.issn.1004-3934.2015.05.012]
[2]周小琳 何泉.替格瑞洛在急性冠脉综合征合并慢性肾脏病患者中的应用研究进展[J].心血管病学进展,2019,(5):718.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.014]
ZHOU Xiaolin,HE Quan.Ticagrelor in Acute Coronary Syndrome with Chronic Kidney Disease[J].Advances in Cardiovascular Diseases,2019,(3):718.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.014]
[3]肖亚楠 高传玉 朱中玉.低剂量替格瑞洛在冠心病中的应用前景[J].心血管病学进展,2020,(7):706.[doi:10.16806/j.cnki.issn.1004-3934.2020.07.009]
XIAO Yanan,GAO Chuanyu,ZHU Zhongyu.Application Prospects of Low-dose Ticagrelor in Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2020,(3):706.[doi:10.16806/j.cnki.issn.1004-3934.2020.07.009]
[4]陈凯磊 胡闻竹 苏冠华.P2Y12抑制剂与癌症风险的相关性研究进展[J].心血管病学进展,2020,(8):798.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.004]
CHEN Kailei,HU Wenzhu,SU Guanhua.Advances in Studies on the Correlation between P2Y12 Inhibitors and Cancer Risk[J].Advances in Cardiovascular Diseases,2020,(3):798.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.004]
[5]肖雨尘 赵仙先 马丽萍.急性冠脉综合征患者提前停服替格瑞洛现象的研究进展[J].心血管病学进展,2020,(11):1120.[doi:10.16806/j.cnki.issn.1004-3934.2020.11.000]
Acute Coronary Syndrome.Premature Ticagrelor Discontinuation in Patients with[J].Advances in Cardiovascular Diseases,2020,(3):1120.[doi:10.16806/j.cnki.issn.1004-3934.2020.11.000]
[6]周锐 赵飞飞 钱阳 余文静 王大新..氯吡格雷与替格瑞洛的安全性和有效性在东亚急性心肌梗死患者的比较：系统回顾和荟萃分析[J].心血管病学进展,2021,(6):560.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.020]
ZHOU RuiZHAO Feifei QIAN YangYU WenjingWANG Daxin.Comparison of the Safety and Efficacy of Clopidogrel Versus Ticagrelor in Patients with Acute Myocardial Infarction in East Asia:a Systematic Review and Meta-Analysis[J].Advances in Cardiovascular Diseases,2021,(3):560.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.020]
[7]王晓妍 崔炜.替格瑞洛治疗急性冠脉综合征时引起缓慢性心律失常的研究进展[J].心血管病学进展,2021,(7):642.[doi:10.16806/j.cnki.issn.1004-3934.2021.07.016]
WANG Xiaoyan,CUI Wei.Bradyarrhythmia Caused by Ticagrelor in Treatment of Acute Coronary Syndrome[J].Advances in Cardiovascular Diseases,2021,(3):642.[doi:10.16806/j.cnki.issn.1004-3934.2021.07.016]